The Food & Drug Administration (FDA) has recently given Fast Track status to a new therapy called AlloNK® (also known as AB-101), which is being studied as a potential treatment for lupus nephritis, a type of kidney disease caused by lupus. AlloNK is made from natural killer (NK) cells, a part of our immune system, and is used alongside other drugs like rituximab or obinutuzumab to enhance their effectiveness. It works by targeting certain immune cells to reduce the production of harmful antibodies and lessen the activity of lupus.
Unlike some other therapies, AlloNK comes frozen and is simple to administer without the need for complex follow-up procedures. It’s also designed to be safer, with no genetic modifications and no associated cancer risks, unlike some other advanced treatments.
Currently, AlloNK is being tested in an early-stage clinical trial involving people with lupus nephritis who haven’t seen improvement with standard treatments or who have had their disease return. Keep an eye on updates from the Lupus Foundation of America for more information on this and other lupus-related drug developments. Learn more about new treatments being researched for lupus.
Read The Announcement
